Telegram RegisterThe public register of Telegram
Telegram profile photo for 팔칠사공스토너 실전투자 인사이트

Channel

팔칠사공스토너 실전투자 인사이트

@stoner8740

On this record: Topic · Growth · Engagement · Posts · Posts edited after publishing · Citations · Cite this entry

11,035subscribers

+7 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1002378754614
TypeChannel
Username@stoner8740
CreatedBetween 1 September 2024 and 31 March 2025 — estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded6 August 2026
Last confirmed live18 September 2026
Measurements held31
Confirmed unchanged1 time, most recently 18 September 2026
On Telegramt.me/stoner8740

Topic

Crypto & trading — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 11 September 2026 and assigned it the closest of 31 fixed categories, at 83% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.

Growth

10,98011,05111,015.56 August 2026 — 11,028 subscribers7 August 2026 — 11,034 subscribers7 August 2026 — 11,030 subscribers8 August 2026 — 11,025 subscribers9 August 2026 — 11,029 subscribers10 August 2026 — 11,027 subscribers12 August 2026 — 11,023 subscribers16 August 2026 — 11,026 subscribers17 August 2026 — 11,027 subscribers18 August 2026 — 11,023 subscribers19 August 2026 — 11,051 subscribers20 August 2026 — 11,049 subscribers21 August 2026 — 11,039 subscribers23 August 2026 — 11,016 subscribers25 August 2026 — 11,008 subscribers26 August 2026 — 11,013 subscribers27 August 2026 — 11,017 subscribers28 August 2026 — 11,018 subscribers29 August 2026 — 11,016 subscribers30 August 2026 — 11,013 subscribers31 August 2026 — 11,009 subscribers1 September 2026 — 11,005 subscribers2 September 2026 — 10,993 subscribers3 September 2026 — 10,987 subscribers4 September 2026 — 10,988 subscribers7 September 2026 — 10,980 subscribers10 September 2026 — 10,981 subscribers12 September 2026 — 10,982 subscribers14 September 2026 — 10,987 subscribers16 September 2026 — 11,022 subscribers18 September 2026 — 11,035 subscribers11,0356 August 202618 September 2026
31 measurements spanning 44 days, net +7. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 10,969–11,062 and does not start at zero.
Measurement log — every subscribers count we have recorded, most recent 20 of 31
Measured (UTC)SubscribersChange
18 Sept 2026, 17:5611,035+13
16 Sept 2026, 07:1811,022+35
14 Sept 2026, 10:3610,987+5
12 Sept 2026, 22:0210,982+1
10 Sept 2026, 21:3710,981+1
7 Sept 2026, 21:2010,980-8
4 Sept 2026, 23:4110,988+1
3 Sept 2026, 09:3310,987-6
2 Sept 2026, 04:2510,993-12
1 Sept 2026, 03:3611,005-4
31 Aug 2026, 00:5311,009-4
30 Aug 2026, 00:2711,013-3
29 Aug 2026, 03:0411,016-2
28 Aug 2026, 03:3711,018+1
27 Aug 2026, 05:5611,017+4
26 Aug 2026, 02:4611,013+5
25 Aug 2026, 00:0711,008-8
23 Aug 2026, 08:4711,016-23
21 Aug 2026, 17:0811,039-10
20 Aug 2026, 11:5211,049first reading

Engagement

375 posts held, back to 5 August 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 41 pages of Telegram’s post history, 20 posts per page.

ERR · 30 days
24.8%
avg views ÷ 11,035 subscribers
Avg views / post
2,740
133 posts measured
Reaction rate
this channel exposes no reaction counts
Posts in window
134
of 375 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 3 September 2026
Posts held375 (5 August 20263 September 2026)
Views total364,000
Reactions total
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken3 Sept 2026, 02:15 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

Recent posts

3 Sept 2026, 01:09 UTC≈1,190 viewsread 3 September 2026
Photo

GC녹십자웰빙 도입 지방분해 신약, 中 3상 주요 평가지표 충족 2026.09.03·10:08:09·머니투데이 [머니투데이 정기종 기자] 'RZL-012' 1회 투여로 위약군보다 반응률 30%포인트 이상 높은 결과 확인중국 품목허가 신청 추진…GC녹십자웰빙, 국내 독점 권리 기반 사업화 기대GC녹십자웰빙이 국내 독점 권리를 확보한 지방분해 신약 후보물질 'RZL-012'가 중국 임상 3상에서 주요 유효성·안전성 평가지표를 충족했다. 중국에서 품목허가 신청을 추진하는 가운데 국내 사업화에도 속도가 붙을 전망이다. GC녹십자웰빙은 파트너사 라지엘테라퓨틱스의 RZL-012가 중국 임상 3상에서 주요 유효성·안전성 평가지표를 충족하는 주요 결과를 확보했다고 3일 밝혔다. 이번 임상은 라지엘의 중국 파트너사 푸싱제약 계열사 주브스타가 성인 이중턱

Signed 팔칠사공

2 Sept 2026, 23:40 UTC≈1,430 viewsread 3 September 2026
Forwarded from @hmsecresearch

[현대차증권 제약/바이오/의료기기 김현석] 한올바이오파마(009420) BUY/93,000 (유지/유지) 미국 파트너사 대비, 경쟁사 대비 저평가 지속 ■ 미국 파트너사 이뮤노반트 대비 저평가 지속 - 미국 파트너사 이뮤노반트는 난치성 류마티스 관절염(D2T RA) Period 1 결과 발표 이후 52주 신고가 경신하며 시가총액 12조원 수준까지 상승. 반면 한올바이오파마의 시가총액은 3조원에 미치지 못하는 상황으로 이뮤노반트 시가총액 대비 한올바이오파마의 시가총액 비중은 최근 3년 내 최저 수준 - 이뮤노반트가 IMVT-1402 판매로 얻을 수 있는 예상 영업이익률과 한올바이오파마에게 지급하는 판매로열티 고려 시 한올바이오파마의 시가총액은 이뮤노반트 시가총액의 50% 수준을 적정 가치로 판단. 이를 감안했을 때 현재 25% 수준에서는 이뮤

Signed 스토너

2 Sept 2026, 22:26 UTC≈2,060 viewsread 3 September 2026
Photo

Photo, posted without a caption

Signed 팔칠사공

2 Sept 2026, 22:24 UTC≈2,390 viewsread 3 September 2026
Photo

Photo, posted without a caption

Signed 팔칠사공

2 Sept 2026, 22:09 UTC≈1,540 viewsread 3 September 2026
Forwarded from @bio_shinhanPhoto

미국 바이오 지수 NBI 3일 연속 상승 중. 머크, 노바티스 모두 역사적 신고가 수준 근접 머크는 지난 5월 할로자임 특허 승소 및 키트루다SC 빠른 성장, 모더나 mRNA 항암 백신 병용 3상 성공 후 역사적 신고가 및 지속 상승 중 어제 알테오젠과 계약한 노바티스도 2025년 10월 Avidity 16.4조원 인수 발표 후 역사적 신고가 다시 근접 중

Signed 스토너

2 Sept 2026, 22:08 UTC≈2,240 viewsread 3 September 2026
Photo

Photo, posted without a caption

Signed 팔칠사공

2 Sept 2026, 21:39 UTC≈3,320 viewsread 3 September 2026
Photo

#스토너미국장 1. 미국 증시는 최근 금리와 유가 부담으로 이어졌던 조정 이후 반등했습니다. 다만 8월 ADP 민간 고용의 둔화와 기업 설비투자를 보여주는 핵심 자본재 주문도 정체된 모습이어서 경기 자체가 강해서 오른 시장은 아니었습니다. 오히려 고용 둔화가 연준의 추가 긴축 부담을 낮출 수 있다는 기대가 일부 반영된 것으로 보입니다. 지금은 금리 우려가 매우 높기에 bad is good인 상황입니다. 2. 이날 시장에서 눈에 띈 것은 중소형주 러셀이 대형 지수보다 강했고 지역 은행도 상승했는데, 고용 둔화로 금리 부담이 일부 완화되면서 그동안 금리에 민감했던 업종으로 수급이 이동한 것으로 보입니다. 항공주 역시 최근 유가 상승 부담에도 반등했습니다. 반도체 한 곳으로만 자금이 몰린 것이 아니라 금리에 눌렸던 NON-AI 영역까지 순환매가

Signed 팔칠사공

2 Sept 2026, 11:28 UTC≈2,740 viewsread 3 September 2026

https://finance.yahoo.com/healthcare/articles/alteogen-enters-option-license-agreement-110000294.html #알테오젠 1. 알테오젠이 노바티스와 ALT-B4 기반 피하주사 제형 개발을 위한 독점적 옵션, 라이선스 계약을 체결했습니다. 2. 노바티스는 복수의 바이오의약품을 피하주사 제형으로 개발하고 상업화할 수 있는 권리를 옵션 형태로 확보했습니다. 3. 모든 옵션 행사와 개발, 상업화 마일스톤 달성 시 계약 규모는 최대 32억2,300만달러, 약 4조4,165억원입니다. 4. 상업화 이후에는 계약 금액과 별도로 제품 순매출에 연동된 로열티도 알테오젠이 받습니다. 5. 구체적인 적용 품목은 공개되지 않았으며, 최대 금액은 옵션 행사와 개발 성공을 전제로 한다는

Signed 스토너

2 Sept 2026, 07:51 UTC≈3,210 viewsread 3 September 2026
Photo

오늘 알테오젠 공시보고 샀다가 조금이라도 용돈벌이로 매수했는데 손절쳤습니다. 덩치가 커졌다는걸 느낍니다. 예전 올릭스는 릴리 계약금 비공개 9천억대로 3연상을 갔는데 역시 덩치가 커진 알테에겐 장대양봉을 기대하기 힘들만큼 그만큼 스타가되었네요

Signed 팔칠사공

2 Sept 2026, 04:26 UTC≈2,120 viewsread 3 September 2026

📌 알테오젠(시가총액: 21조 10억) #A196170 📁 투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALT-B4 독점적 옵션·라이선스 계약 체결) 2026.09.02 13:26:34 (현재가 : 301,500원, +0.17%) 제목 : 재조합 인간 히알루로니다제 제품 ALT-B4 독점적 옵션·라이선스 계약 체결 * 주요내용 ※ 투자유의사항 본 계약은 의약품규제기관의 허가가 완료되어야 이행되는 조건부 계약으로서, 본 계약을 통한 수익 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라, 규제기관에 의한 연구 개발의 중단, 품목허가 실패 등 발생시 계약이 해지될 수 있습니다. 1. 계약상대방: Novartis Pharma AG (스위스) - Novartis 최근

Signed 팔칠사공

2 Sept 2026, 02:47 UTC≈3,170 viewsread 3 September 2026

https://pharm.edaily.co.kr/News/Read?newsId=02801126645576184&mediaCodeNo=257 김주희 인벤티지랩 대표는 지난 1일 경기 성남시 본사에서 이데일리와 만나 “최근 체결된 다수의 mta가 ivl-바이오플루이딕 관련 계약”이라며 “현재 파트너사로부터 실제 개발 물질을 받아 각 항체에 ivl-바이오플루이딕을 적용할 수 있는지 검증하고 있다”고 말했다

Signed 팔칠사공

1 Sept 2026, 14:26 UTC≈1,220 viewsread 1 September 2026

에이비엘바이오 지바스토믹, 10월 승부처…mPFS 주목 ESMO서 임상 1b상 후속 데이터 공개 12mpk mPFS 주목…8mpk 16.9개월 ABL001도 구두발표…세부 분석 주목 https://www.medipana.com/news/articleView.html?idxno=416850&sicode=01 #에이비엘바이오 에이비엘바이오는 오는 10월 ESMO가 상당히 중요한 승부처입니다. 핵심은 지바스토믹의 단순 ORR이 아니라 12mg/kg 투여군의 mPFS와 저발현 환자 데이터입니다. 현재까지 지바스토믹은 니볼루맙·화학항암제 병용에서 8mg/kg ORR 77%, mPFS 16.9개월 12mg/kg ORR 73%, mPFS 미도달 6개월 무진행생존율 8mg 73%, 12mg 91% 3등급 이상 치료 관련 이상반응 약 56% 을 기록했습

Signed 팔칠사공

Showing the 12 most recent of 375 posts we hold for @stoner8740. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Posts edited after publishing

@stoner8740 edited 1 post after it first published — the same permalink now carries different wording than the one this register originally read, caught because our own crawl held a copy of the earlier text.

An edit is not deception. Typo fixes, price updates and corrections look exactly like this too — this register can tell you the wording changed and when, not why. How this is measured.

First edit seen
9 August 2026
Most recent edit
9 August 2026

Forward network

Republishes

Channels on the register whose posts this channel has forwarded.

[신한 리서치본부] 제약/바이오
@bio_shinhan · 21,437
7 posts
에이프릴바이오 공식IR채널: 리레이팅 2026
@aprilbioipr · 4,498
6 posts
BioMoment
@BioMomentOncology · 1,061
4 posts
🧬바이오섹터 분석🧬 [그로쓰리서치]
@growthbio · 13,359
4 posts
더파마 뉴스·인사이트| THE PHARMA
@BBAinsights · 1,075
3 posts
앱클론 IPR
@abclonipr · 1,729
3 posts
AWAKE - 실시간 주식 공시 정리채널
@darthacking · 65,096
3 posts
텐베거 인생을 위하여
@decapitaionforce · 635
3 posts
디앤디파마텍 공식 IR 채널
@dndpharmatech · 3,638
3 posts
한경바이오인사이트
@hkbioinsight · 4,296
3 posts
나혼주
@nahonju · 2,118
3 posts
더바이오 뉴스룸
@thebio111 · 6,513
3 posts
한양증권 제약/바이오 오병용
@bdragon0808 · 13,384
2 posts
미래에셋 제약/바이오 김승민
@bioksm · 14,926
2 posts
작업중이양
@eyang92 · 7,484
2 posts
올릭스(주) - OliX Pharmaceuticals
@olix_official · 3,804
2 posts
순대렐라의 바이오 하우스
@BIOWORLDJD · 4,062
1 post
MJ의 Bio & Healthcare
@BarbarianBHC · 4,955
1 post
바이오파마봇 레이더 v1.0
@BiopharmaBot_News · 204
1 post
[Public] 파이낸스 스코프
@FS_public_channel · 845
1 post
하나증권 리서치
@HanaResearch · 24,968
1 post
한투 제약/바이오 위해주
@KIS_Healthcare · 8,925
1 post
Plan G Research
@Plan_G_Research · 6,365
1 post
Yeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,309
1 post
바이오 BOSS
@allbioboss · 433
1 post
1년에 1랩업
@fordouble · 2,710
1 post
💰월급으로부터해방💶
@freedomfromsalary · 610
1 post
[충간지의 글로벌 의료기기/디지털 헬스/로보틱스 연구소]
@globalmedtech · 12,102
1 post
한국경제
@hankyung_fin · 12,714
1 post
현대차증권_리서치센터_채널
@hmsecresearch · 8,580
1 post
호그니엘
@hogniel · 15,327
1 post
허혜민의 제약/바이오 소식통
@huhpharm · 24,282
1 post
마켓타임스 뉴스룸
@markettimesnews · 81
1 post
BUY(!)BUY(!)바이오🤡DS 제약/바이오 김민정
@mnJeong_BIO · 7,896
1 post
NH 리서치 [제약/바이오]
@nhis_bio · 4,937
1 post
요약하는 고잉
@one_going · 47,233
1 post
Rafiki research
@rafikiresearch · 20,596
1 post
알지노믹스 공식 IR/PR 채널
@rznomics · 1,139
1 post
스몰인사이트리서치
@smallinsightresearch · 5,723
1 post

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

Named by

Channels on the register whose posts name this channel's handle.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 18 September 2026 — this entry's latest reading, not the date you are reading this.

“팔칠사공스토너 실전투자 인사이트” (@stoner8740), 11,035 subscribers as measured 18 September 2026. Telegram Register, tgregister.com/channel/stoner8740.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.